reason report
rais estimate reflect nerv block label expans exparel
call discuss last friday fda approv supplement indic
exparel light updat label manag commentari
rais sale exparel
although kept estim essenti unchang
near term expect exparel sale benefit
continu effort growth shoulder surgeri via nerv block
partial off-set pull-back off-label use nerv block
type surgeri medium term see growth increas
penetr shoulder surgeri fda approv came surpris
especi given concern rais recent adcom howev
approv also indic fda commit approv new
altern help address opioid crisi rais
pt reflect increas sale project
exparel maintain mp rate believ
appropri reflect stock current level longer term
remain cautiou long-term growth prospect exparel
given posit phase data outlin
march link medium term see upsid exparel get
j-code design potenti start unbundl
current reimburs design surgic suppli
continu look better visibl could play
updat label provid guidelin usag exparel nerv
block believ net posit new exparel label
specif recommend exparel region analgesia via interscalen
brachial plexu nerv block clearli import segment
manag expect region nerv block procedur
within next two year brachial plexu block howev
fda specif highlight concern result two femor
nerv block studi total knee arthroplasti intercost nerv
block studi posterolater thoracotomi lung/ esophagu
recommend approv indic believ
off-label util exparel nerv block
current sale new label posit util
shoulder surgeri neg off-label surgeri knee
thorac region net-net near term believ factor
off-set chang exparel number
longer term believ label drive meaning util
shoulder surgeri current under-penetrated area exparel
rais exparel number
dcf use wacc
termin growth rate
net debt total capit
per share exclud short-term
compani inform leerink partner llc research
revenu
pleas refer page import disclosur price chart analyst certif
rx trend deriv im health
near-term focu exparel prescript growth
potenti j-code start watch uptak
exparel year fuel collabor
look im data exparel each regist im grew y/i
first two month year each grew averag
y/i estim impli y/i each
inject growth howev note manag issu
exparel guidanc neg adcom decis
state believ guidanc appropri conserv
would surpris guidanc rang revis upward
slightli confer call earli may growth could
come j-code design public meet would occur
may potenti decis late year issu design
start pacira could also receiv j-code on-going
discuss washington enact legisl measur respons
section opioid commiss report permit review
modifi rate-set polici discourag use non-opioid
treatment pain manag remain confid abil get
j-code design start consid nerv
block approv posit read-through j-code design
like come
uptak shoulder could fast pursuit broader label
still determin manag note nerv block
upper extrem difficult indic infiltr
approv pacira expect rapid adopt exparel
surgeri type pacira would util sale forc reach
anesthesiologist given exist relationship usag also
grow sports-rel procedur pacira expect sale forc
driver growth well manag could see modest
chang sale forc new indic broader
nerv block label pacira expect discuss fda
addit trial expect requir label
point remain seen manag ultim go
believ pacira exparel non-opioid post-op pain manag continu
grow driven commerci collabor sale
believ well understood investor long-term growth may impact
entri heron better clinic profil -- longer durat pain relief hour vs
hour easier administr instil vs infiltr note signific upsid
potenti exist exparel assign separ j-code howev limit visibl
rate pacira stock market perform mp price target
figur chang model
lp estim note number except ep
pt base dcf forecast cash flow use
wacc termin growth rate
phase studi success limit impact collabor potenti competit
heron
number except per share data
royalti
net debt ebitda ratio
figur except per share data
collabor licens develop revenu
sourc press releas transcript sec file
number except per share data
prepaid expens
current portion defrer revenu
accumul comprehens loss
number except per share data
adjust reconcil ni net cash oper
amort unfavor leas oblig debt issuanc cost
amort debt discount
loss dispos fix asset
loss extinguish debt
decreas increas work capit
purchas fix asset capital-expenditure
purchas invest
sale invest
payment conting consider
net invest
proce exercis stock option warrant
proce share issu employe stock purchas plan
convers princip equiti compon convert senior
net financ
net chang equival
